They needed the CR to cover the 45-60day lag in receipts.
At 2000 patients a month increasing even at 50-100% per month, it’ll still take 2-3 qtrs to cover cash costs.
On these figures given by BOT, the monthly revenue growth doesn’t really kick in to $20mill plus until H2 2025 CY. Add the 45-60 day payment cycle, BOT basically now have about $85 mill to cover until the Dec qtr.
$45-48 mill wasn’t going to last 3 qtrs with the rising cost of doing business.. Instos saw that, and the market correction helped make their job easier.. IMO.
Ann: Botanix $40 Million Capital Raising for Sofdra Rollout, page-145
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.025(8.62%) |
Mkt cap ! $617.6M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 32.5¢ | 29.5¢ | $3.773M | 12.14M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 105056 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 29998 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |